Cell-based therapy offers promising treatment solutions for many devastating and currently incurable diseases such as Parkinson’s, Alzheimer’s, stroke, and cancer. However, the lack of means to effectively track these therapeutic cells in a subject to assess treatment safety and effectiveness lengthens the time for development and introduction of these therapies to clinics.
This is why we founded Visicell Medical Inc. We are a team of a passionate scientist, engineer, and radiologist who began this journey with a singular goal: to help accelerate cell-based therapy to the market for patients in need. We all have been personally touched by the need of such promising therapy for our family, friends and colleagues. With our technology, our objective is to make such breakthroughs possible for patients.
Our current suite of imaging tools empower scientists and clinicians to evaluate cell therapy in a faster, more cost-effective way early on in development, and understand safety and performance with continuity from pre-clinical stage to clinical trials. At Visicell, we strive to transform how biopharmaceutical products are developed and taken to market with our proprietary nanomaterial technology.
Our Innovative Technology
Visicell Medical’s core technology is based on clinically applicable imaging tool published in Nature Medicine in 2012. Our Co-Founder, Mya S. Thu, is the first author of the article, and one of the inventors of the core technology. We have since further developed the technology for a fast, easy-to-use, and all-in-one solution that is applicable to different immune (CAR-T and NK) and stem cell types. Based on the imaging needs of specific disease models in a subject, we have also additionally expanded the technology for dual imaging modality. Visicell Medical centers its technological and product development philosophy on clinical applicability using standard imaging techniques available in today’s clinic such that its customers and clients are able to perform their studies with continuity from pre-clinical to clinical trials with minimal adaptations.
The Visicell Medical Team
Mya Thu, M.Sc., MBA
Co-Founder and CEO
Mya is the Co-Founder and President/CEO of Visicell Medical Inc. She has a unique passion to transform how much-needed technologies are developed and life-saving products are taken to market for patients based on her own personal family experience. She has more than twelve years of experience in nanomaterials, stem cell imaging, and stem cell-based therapy in neurodegenerative diseases, and have obtained her career training at prominent institutions including City of Hope Medical Center (COH) and National Institutes of Health (NIH). She is a trained Biomedical-Electrical Engineer and holds a Masters in Medical Device and Diagnostic Engineering from the University of Southern California (USC) and a Masters in Business Administration (MBA) from the Rady School of Management, University of California, San Diego (UCSD).
Amil Gentili, MD, MBA, FACHE
Co-Founder and VP, Clinical Operations
Amil is a Co-Founder of Visicell Medical Inc. He is a practicing radiologist and a Professor of Radiology at University of California, San Diego (UCSD). He has more than twenty-five years of medical imaging and healthcare management experience with extensive publications in peer-reviewed journals. In addition to medical training, Amil holds a Masters in Business Administration (MBA) from the Rady School of Management, UCSD.
Mark Stolowitz, PhD
Chief Science Officer
Mark retired in May of 2019 as the Deputy Director for Operations in the Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University School of Medicine. He joined Visicell Medical Inc. as the Chief Science Officer in March of 2021. A seasoned scientific leader with over 35 years of experience conceptualizing and developing innovative life sciences research tools, he is acknowledged for creating technology platforms and developing intellectual property to facilitate new business segments and startup ventures, realize new market opportunities and create mergers and acquisitions opportunities. Over the course of 20 years, Mark served as either Chief Executive Officer or Chief Technology Officer in five start-up companies in the life sciences research tools industry. A prolific innovator, he has been issued 47 United States Patents related to Bioconjugation, Protein Chromatography, Protein Immobilization, Nucleic Acid Immobilization, Protein Biochips, SPR Biosensors, and Protein Sequencing.
Co-founder and Chair of SAB
Professor of Medicine and Director of Cell Therapy
Johnny Akers, PhD
VP, Scientific Operations and Alliance Management
Johnny leads our research and product development program with his strong analytical skill and extensive training in biochemistry and molecular cell biology. Prior to joining Visicell, he was an assistant project scientist at UC San Diego Moores Cancer Center developing novel exosome nanoparticle-based diagnostic and therapeutic tools for treating brain cancer. Johnny holds a PhD in biological sciences from University of California Irvine.
Please visit the News page to to learn more about what the media is saying about Visicell.